Non-stimulant ADHD treatments fill defined clinical roles. The first-line stimulants (methylphenidate, amphetamine) have stronger efficacy data in most populations, but non-stimulants are essential for patients with stimulant intolerance, contraindications, substance use concerns, particular symptom patterns, or preference. Atomoxetine, viloxazine, and the alpha-2 agonists (guanfacine, clonidine) each have specific mechanisms, evidence base, and clinical fit. The longevity-psychiatry frame uses non-stimulants where they are the right answer, not as a default avoidance of stimulants.
Atomoxetine is the most evidence-based non-stimulant. Norepinephrine reuptake inhibitor with high selectivity; works through prefrontal cortex enhancement rather than the broader catecholaminergic effects of stimulants. Effective in adult and pediatric ADHD with effect sizes smaller than stimulants but clinically meaningful. Dosing: 40mg starting dose, titrate to 80mg over 2–4 weeks, maximum 100mg. Onset is gradual; full effect typically takes 4–6 weeks. Adverse effects: GI symptoms (nausea, decreased appetite), modest BP/HR increase, sexual dysfunction, rare hepatotoxicity (monitor LFTs at baseline, periodically), rare suicidal ideation (boxed warning, particularly in young patients).
Viloxazine is the newer NRI alternative. FDA-approved 2021 (qelbree). Similar mechanism to atomoxetine with possibly faster onset and somewhat different adverse effect profile. Dosing: 200mg starting in adults (100mg in children), titrate to 400–600mg as tolerated. Adverse effects: somnolence, decreased appetite, headache, irritability, increased BP/HR. Insurance coverage is variable; the role versus atomoxetine is still being characterized in clinical practice.
Alpha-2 agonists — guanfacine and clonidine — have specific clinical place. Extended-release guanfacine (Intuniv) 1–4mg in children and adolescents, with adult use increasing; effective for hyperactivity, impulsivity, emotional regulation, sleep onset; particularly useful when these features predominate. Extended-release clonidine (Kapvay) 0.1–0.4mg has similar indications with somewhat different tolerability profile. Both are useful as adjuncts to stimulants when stimulant alone produces inadequate response; both are useful as monotherapy when stimulants are inappropriate. Adverse effects: sedation, BP decrease (sometimes a problem, sometimes desired), bradycardia, withdrawal hypertension if abruptly discontinued.
The clinical fit matters. Patients with substance use disorder history frequently benefit from non-stimulant first-line — atomoxetine or guanfacine — given lower abuse potential. Patients with cardiovascular contraindications to stimulants may tolerate atomoxetine or alpha-2 agonists, though monitoring is still required. Patients with prominent hyperactivity, impulsivity, or sleep-onset difficulty may benefit from guanfacine combination or monotherapy. Patients with comorbid anxiety often respond well to atomoxetine, which has some independent anxiolytic effect. Patients with tic disorder comorbid with ADHD often benefit from guanfacine since stimulants may worsen tics.
The combination strategy. Stimulant plus non-stimulant combinations are clinically useful in patients with inadequate response to either alone. Stimulant plus guanfacine is the most common combination, with the stimulant addressing core attentional symptoms and the guanfacine addressing hyperactivity, sleep, or emotional regulation. The combination requires more monitoring but produces benefit in selected patients. The discipline is to know the non-stimulant options well, recognize the clinical scenarios where they are first-line, and use combination strategies when appropriate. Most ADHD patients respond best to stimulants alone or to stimulant-plus-non-stimulant combinations; the non-stimulants alone are essential for selected populations where stimulants are not the answer.